1 / 20

ASCO Viewing Presentation

ASCO Viewing Presentation. Title: Estrogen receptor alpha ( ESR1 ) gene amplification status and clinical outcome in tamoxifen -treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. (19 slides ) Oral Abstract Session

brosh
Télécharger la présentation

ASCO Viewing Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ASCO Viewing Presentation Title: Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. (19 slides) Oral Abstract Session Tumor Biology Track 2012 ASCO Annual Meeting Chair(s):  Robert Arthur Kratzke, MD; Priyanka Sharma, MD; Presentation Author:
Christian Singer, MD Subcategory:  Genomic and Epigenomic Biomarkers Category:  Tumor Biology Meeting:  2012 ASCO Annual Meeting Session Type and Session Title:  Oral Abstract Session, Tumor Biology Abstract Number:  10501 Citation:  J ClinOncol 30, 2012 (suppl; abstr 10501) Competing Financial Interests: The University Medical Centre Hamburg-Eppendorf has filed a patent application for certain technology described in this presentation.

  2. Estrogenreceptoralpha (ESR1) geneamplificationstatusandclinicaloutcome in tamoxifen-treated postmenopausal patientswithendocrine-responsiveearlybreastcancer: An analysisoftheprospective ABCSG-6 trial Christian F Singer & FrederikHolst, Stefan Steurer, EikeBurandt, HellmutSamonigg, SigurdLax, RaimundJakesz, MargarethaRudas, Herbert Stöger, Richard Greil, Otto Dietze, Guido Sauter, Martin Filipits, Ronald Simon & Michael Gnant, on behalf of ABCSG

  3. EstrogenReceptor - Background • expressed in 70% of invasive breastcancercases • establishedprognosticparameter • predictsresponsetoendocrinetherapy • actsas DNA-bindingtranscriptionfactor • 2 receptorsubtypes (ERaandERb) • ERaisencodedbyESR1 gene Thomas & Gustafsson, Nature Med 2011

  4. Biological Rationale • 5 yearsofadjuvant TAM reduce 15-year risksofrecurrenceanddeath in ER+ breastcancer • In neoadjuvantsetting: responsetoTAM dependson theamountofER proteinexpression • ER IHC standardmethod but inaccurate • Technical reasons (tissuepreparation,stainingprotocols,...) • Analytical reasons (cut-off forpositivity, interpretation,...) • ESR1copynumberstatussuperiorprognosticparameter in ER+ breastcancer? EBCTCG, Lancet 2011 Ellis et al., JCO 2001 Hammond et al., JCO 2010

  5. Study Objective • Toinvestigate the value of ESR1copy number status in predicting the long-term clinical outcome in TAM-treated postmenopausal women with endocrine-responsive breast cancer

  6. ABCSG 6 - Synopsis • Designedtodeterminewhethertheadditionofaminoglutethimide (ORI) to TAM improvesoutcome in postmenopausal womenwithhormonereceptor-positive earlystagebreastcancer • Prospectivelydesignedrandomizedmulticentertrial; 2021 patientsrandomizedbetween 1990 and 1995 • 5y of TAM vs 5y of TAM + 2 yofORI • 5 y DFS: 83,7% vs 83,6% (p=0,89), OS: 91,2% vs 92.4% (p=0,74) • Long-term FU and FFPE tumorsamplesavailable Schmid et al., JCO 2003

  7. ABCSG6 - Key elegibilitycriteria • Histologicallyconfirmedprimarybreastcancer • Stage I or II disease • Postmenopausal status • ER and / orPgRpositivity • Knownnodalstatus • Nopriorsystemicanticancertreatment

  8. ABCSG 6 - Study Flow

  9. ESR1CopyNumber Status by FISH CEP6 ESR1 Normal copynumber: ESR1/CEP6 Ratio ≤ 1 Low Level Gain: ESR1/CEP6 Ratio > 1 to <2.0 Amplification: ESR1/CEP6 Ratio ≥ 2.0 Holst et al., Nature Genetics 2007

  10. ESR1CopyNumber Status by FISH No ESR1 amp/gain ESR1 amp/gain Normal copynumber: ESR1/CEP6 Ratio ≤ 1 Low Level Gain: ESR1/CEP6 Ratio > 1 to <2.0 Amplification: ESR1/CEP6 Ratio ≥ 2.0 Holst et al., Nature Genetics 2007

  11. Patient Characteristics

  12. Receptor Status

  13. ESR1CopyNumber Status and ER Expression Chi-Quadrat, Pearson: p<0.0001

  14. Cox proportional hazard modelsDistant RFS and BCSS

  15. DistantRecurrence-Free Survival(Allred Score)

  16. DistantRecurrence-Free Survival(ESR1CopyNumber Status) /gain /gain

  17. BreastCancer-SpecificSurvival(Allred Score)

  18. BreastCancer-SpecificSurvival(ESR1CopyNumber Status) /gain /gain

  19. Conclusions • ESR1 copy number increase in 47% of ER positive breast cancer cases • ESR1 copy number status is significantly correlated with ER protein expression in IHC • ESR1copy number status is a predictor for long-term distant recurrence-free and breast cancer-specific survival in TAM-treated postmenopausal women • Standardized criteria for identification of ESR1 amp/gain urgently needed

  20. Acknowledgements Institute ofPathology, Universitätsklinikum Hamburg Eppendorf • Frederik Holst • Ronald Simon • Stefan Steurer • Eike Burandt • Guido Sauter Austrian BreastandColorectalCancer Study Group (ABCSG) • Michael Gnant • Martin Filipits • Raimund Jakesz • Hellmut Samonigg • Sigurd Lax • Margaretha Rodas • Herbert Stöger • Richard Greil • Otto Dietze ABCSG Study Nurses, Investigators Patientsparticipating in ABCSG 6

More Related